Free Trial

Oscar Health (OSCR) Financials

Oscar Health logo
$13.92 -1.09 (-7.26%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$14.08 +0.15 (+1.11%)
As of 08:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Oscar Health

Annual Income Statements for Oscar Health

This table shows Oscar Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders
25 -271 -606 -573 -407 -261
Consolidated Net Income / (Loss)
26 -271 -610 -571 -407 -261
Net Income / (Loss) Continuing Operations
26 -271 -610 -571 -407 -261
Total Pre-Tax Income
33 -267 -610 -571 -406 -259
Total Operating Income
57 -236 -590 -544 -402 -259
Total Gross Profit
9,178 5,863 683 215 153 80
Total Revenue
9,178 5,863 3,964 1,839 463 488
Operating Revenue
9,178 5,863 3,964 1,839 463 488
Total Cost of Revenue
0.00 0.00 3,281 1,624 309 408
Total Operating Expenses
9,120 6,098 1,273 759 556 339
Selling, General & Admin Expense
1,756 1,426 1,257 265 167 111
Depreciation Expense
32 31 15 - - -
Other Operating Expenses / (Income)
7,333 4,642 - 494 389 229
Total Other Income / (Expense), net
-24 -32 -20 -26 -3.51 0.00
Interest Expense
24 25 23 25 3.51 -
Other Income / (Expense), net
-0.11 -7.08 2.42 -1.20 - -
Income Tax Expense
7.31 3.29 -0.52 0.85 1.05 1.79
Net Income / (Loss) Attributable to Noncontrolling Interest
0.69 0.13 -3.28 1.18 0.00 0.00
Basic Earnings per Share
$0.11 ($1.22) ($2.85) ($3.20) ($14.16) ($9.06)
Weighted Average Basic Shares Outstanding
240.39M 221.66M 212.48M 178.97M 29.26M 28.81M
Diluted Earnings per Share
$0.10 ($1.22) ($2.85) ($3.20) ($14.16) ($9.06)
Weighted Average Diluted Shares Outstanding
265.85M 221.66M 212.48M 178.97M 29.26M 28.81M
Weighted Average Basic & Diluted Shares Outstanding
250.57M 229.73M 216.30M 210.40M - -

Quarterly Income Statements for Oscar Health

This table shows Oscar Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
275 -154 -55 56 177 -150 -65 -16 -40 -226 -193
Consolidated Net Income / (Loss)
276 -153 -54 56 177 -150 -66 -15 -40 -227 -194
Net Income / (Loss) Continuing Operations
276 -153 -54 56 177 -150 -66 -15 -40 -227 -194
Total Pre-Tax Income
288 -154 -52 61 178 -151 -65 -14 -38 -227 -195
Total Operating Income
297 -148 -48 68 186 -145 -58 -6.53 -25 -222 -192
Total Gross Profit
787 5,656 2,423 511 588 3,777 277 340 1,470 577 126
Total Revenue
3,046 2,392 2,423 2,219 2,142 1,432 1,440 1,522 1,470 995 978
Operating Revenue
3,046 2,392 2,423 2,219 2,142 1,432 1,440 1,522 1,470 995 978
Total Cost of Revenue
2,260 -3,263 0.00 1,709 1,555 -2,345 1,163 1,182 0.00 418 853
Operating Cost of Revenue
2,260 - - 1,709 1,555 - 1,163 1,182 - 418 853
Total Operating Expenses
489 5,804 2,472 443 402 3,922 335 346 1,495 799 318
Selling, General & Admin Expense
483 466 460 435 394 364 326 337 399 1,023 79
Depreciation Expense
6.73 9.23 7.50 7.60 7.81 7.74 9.19 8.82 4.94 - -
Total Other Income / (Expense), net
-8.91 -5.96 -3.94 -6.86 -7.08 -5.17 -6.54 -7.73 -12 -4.80 -2.79
Interest Expense
5.99 6.03 5.82 5.99 5.90 6.22 6.13 6.12 6.14 6.14 6.13
Other Income / (Expense), net
-2.92 0.07 1.88 -0.87 -1.18 1.05 -0.41 -1.61 -6.11 1.34 3.34
Income Tax Expense
13 -0.40 2.08 4.64 1.00 -0.81 0.92 1.16 2.02 -0.72 -1.62
Net Income / (Loss) Attributable to Noncontrolling Interest
0.24 0.26 0.21 0.11 0.11 0.19 -0.31 0.10 0.14 -0.51 -0.63
Basic Earnings per Share
$1.10 ($0.68) ($0.22) $0.24 $0.77 ($0.68) ($0.29) ($0.07) ($0.18) ($1.05) ($0.91)
Weighted Average Basic Shares Outstanding
251.28M 240.39M 243.11M 238.67M 231.44M 221.66M 223.10M 219.40M 216.91M 212.48M 212.82M
Diluted Earnings per Share
$0.92 ($0.50) ($0.22) $0.20 $0.62 ($0.68) ($0.29) ($0.07) ($0.18) ($1.05) ($0.91)
Weighted Average Diluted Shares Outstanding
305.94M 265.85M 243.11M 303.97M 293.80M 221.66M 223.10M 219.40M 216.91M 212.48M 212.82M
Weighted Average Basic & Diluted Shares Outstanding
254.68M 250.57M 247.27M 241.91M 237.22M 229.73M 226.11M 221.91M 218.35M 216.30M 214.76M

Annual Cash Flow Statements for Oscar Health

This table details how cash moves in and out of Oscar Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Change in Cash & Equivalents
-341 311 455 282 490 -17
Net Cash From Operating Activities
978 -272 380 -182 223 -165
Net Cash From Continuing Operating Activities
978 -272 380 -182 223 -165
Net Income / (Loss) Continuing Operations
26 -271 -610 -571 -407 -261
Consolidated Net Income / (Loss)
26 -271 -610 -571 -407 -261
Depreciation Expense
32 31 15 15 11 6.90
Amortization Expense
-26 -29 3.19 8.36 2.92 -6.65
Non-Cash Adjustments To Reconcile Net Income
416 -14 490 78 382 79
Changes in Operating Assets and Liabilities, net
530 10 482 289 233 17
Net Cash From Investing Activities
-1,387 577 -227 -775 -345 151
Net Cash From Continuing Investing Activities
-1,387 577 -227 -775 -345 151
Purchase of Property, Plant & Equipment
-28 -26 -29 -26 -14 -26
Purchase of Investments
-2,134 -837 -1,193 -1,810 -1,001 -878
Sale and/or Maturity of Investments
770 1,442 994 1,055 672 1,061
Other Investing Activities, net
3.93 -2.28 1.12 6.68 -1.24 -7.08
Net Cash From Financing Activities
68 6.45 301 1,239 612 -2.12
Net Cash From Continuing Financing Activities
68 6.45 301 1,239 612 -2.12
Repayment of Debt
0.00 0.00 -7.04 -166 -4.84 0.00
Issuance of Debt
0.00 0.00 305 0.00 147 -
Issuance of Common Equity
0.00 2.49 1.85 1,356 0.00 0.00
Other Financing Activities, net
68 3.96 1.30 59 94 0.87
Cash Interest Paid
34 23 10 4.26 0.00 0.00
Cash Income Taxes Paid
0.67 2.41 1.89 0.70 1.53 1.83

Quarterly Cash Flow Statements for Oscar Health

This table details how cash moves in and out of Oscar Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
709 319 -1,059 38 361 470 -922 212 551 -555 -249
Net Cash From Operating Activities
879 347 -500 497 634 297 -1,149 166 415 151 -548
Net Cash From Continuing Operating Activities
879 347 -500 497 634 297 -1,149 166 415 151 -548
Net Income / (Loss) Continuing Operations
276 -153 -54 56 177 -150 -66 -15 -40 -227 -194
Consolidated Net Income / (Loss)
276 -153 -54 56 177 -150 -66 -15 -40 -227 -194
Depreciation Expense
6.73 9.23 7.50 7.60 7.81 7.74 9.19 8.82 4.94 3.74 4.06
Amortization Expense
-7.48 -7.73 -6.54 -5.80 -6.03 -6.32 -7.39 -7.76 -7.13 -1.46 1.19
Non-Cash Adjustments To Reconcile Net Income
309 463 -596 399 151 370 -1,140 311 444 378 -505
Changes in Operating Assets and Liabilities, net
295 36 149 40 304 75 54 -131 12 -2.32 145
Net Cash From Investing Activities
-174 -31 -578 -478 -301 172 225 44 136 -707 299
Net Cash From Continuing Investing Activities
-174 -31 -578 -478 -301 172 225 44 136 -707 299
Purchase of Property, Plant & Equipment
-9.03 -6.82 -7.57 -7.56 -5.95 -6.10 -6.48 -5.62 -7.38 -7.13 -9.62
Purchase of Investments
-337 -110 -660 -806 -557 -215 -84 -335 -203 -850 -31
Sale and/or Maturity of Investments
172 86 87 335 261 396 316 385 346 150 339
Other Investing Activities, net
0.00 -0.01 2.49 0.83 0.63 -2.38 0.62 -0.52 0.00 -0.43 0.53
Net Cash From Financing Activities
4.87 3.82 19 19 27 1.07 2.32 2.55 0.51 0.53 0.42
Net Cash From Continuing Financing Activities
4.87 3.82 19 19 27 1.07 2.32 2.55 0.51 0.53 0.42
Other Financing Activities, net
4.87 3.82 19 19 27 1.07 0.30 2.55 0.04 0.01 0.37
Cash Interest Paid
0.15 11 11 0.15 11 0.26 0.26 11 11 0.27 0.26

Annual Balance Sheets for Oscar Health

This table presents Oscar Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets
4,840 3,601 4,527 3,322 2,272
Total Current Assets
2,845 3,061 4,122 2,306 1,870
Cash & Equivalents
1,527 1,870 1,559 1,104 826
Short-Term Investments
624 690 1,397 587 368
Accounts Receivable
316 201 216 138 65
Other Current Assets
378 300 949 476 611
Plant, Property, & Equipment, net
67 62 60 47 36
Total Noncurrent Assets
1,929 478 345 969 366
Long-Term Investments
1,846 395 250 873 352
Other Noncurrent Operating Assets
82 83 95 97 13
Total Liabilities & Shareholders' Equity
4,840 3,601 4,527 3,322 2,272
Total Liabilities
3,824 2,795 3,634 1,929 1,823
Total Current Liabilities
3,463 2,429 3,264 1,852 1,666
Accounts Payable
432 273 298 235 138
Other Current Liabilities
3,031 2,156 2,966 1,618 1,528
Total Noncurrent Liabilities
361 366 370 77 157
Long-Term Debt
300 299 298 0.00 142
Other Noncurrent Operating Liabilities
61 68 72 77 15
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,016 806 892 1,393 -1,296
Total Preferred & Common Equity
1,014 804 890 1,387 -1,296
Total Common Equity
1,014 804 890 1,387 -1,296
Common Stock
3,870 3,682 3,509 3,394 133
Retained Earnings
-2,851 -2,877 -2,606 -2,000 -1,427
Treasury Stock
-2.92 -2.92 -2.92 -2.92 -2.92
Accumulated Other Comprehensive Income / (Loss)
-1.83 1.31 -9.72 -3.67 0.88
Noncontrolling Interest
2.84 2.15 2.02 5.29 0.00

Quarterly Balance Sheets for Oscar Health

This table presents Oscar Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
5,844 4,483 5,006 4,419 3,350 4,565 4,483 4,309
Total Current Assets
3,775 2,368 3,359 3,504 2,992 4,193 4,131 3,931
Cash & Equivalents
2,237 1,206 2,268 2,231 1,400 2,322 2,110 2,113
Short-Term Investments
751 504 364 616 1,044 1,256 1,325 718
Accounts Receivable
489 301 398 343 207 193 186 215
Other Current Assets
298 357 329 314 340 422 511 885
Plant, Property, & Equipment, net
72 67 64 61 62 63 64 56
Total Noncurrent Assets
1,997 2,048 1,583 854 296 309 288 321
Long-Term Investments
1,904 1,964 1,496 766 207 217 193 224
Other Noncurrent Operating Assets
94 84 87 87 89 92 95 97
Total Liabilities & Shareholders' Equity
5,844 4,483 5,006 4,419 3,350 4,565 4,483 4,309
Total Liabilities
4,508 3,318 3,866 3,385 2,428 3,613 3,551 3,224
Total Current Liabilities
4,149 2,955 3,502 3,019 2,061 3,244 3,182 2,853
Accounts Payable
634 395 348 303 260 262 299 252
Other Current Liabilities
3,515 2,559 3,154 2,716 1,801 2,983 2,882 2,600
Total Noncurrent Liabilities
359 363 364 365 367 369 370 372
Long-Term Debt
300 299 299 299 299 298 298 298
Other Noncurrent Operating Liabilities
59 64 65 66 69 70 71 74
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,336 1,165 1,141 1,034 921 952 932 1,085
Total Preferred & Common Equity
1,333 1,163 1,138 1,032 919 950 930 1,082
Total Common Equity
1,333 1,163 1,138 1,032 919 950 930 1,082
Common Stock
3,902 3,837 3,787 3,737 3,654 3,621 3,583 3,479
Retained Earnings
-2,576 -2,698 -2,643 -2,699 -2,727 -2,661 -2,646 -2,380
Treasury Stock
-2.92 -2.92 -2.92 -2.92 -2.92 -2.92 -2.92 -2.92
Accumulated Other Comprehensive Income / (Loss)
9.60 26 -2.63 -2.59 -4.45 -6.86 -4.48 -14
Noncontrolling Interest
3.07 2.58 2.37 2.26 1.96 2.26 2.16 2.53

Annual Metrics And Ratios for Oscar Health

This table displays calculated financial ratios and metrics derived from Oscar Health's official financial filings.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Growth Metrics
- - - - - -
Revenue Growth
56.54% 47.92% 115.57% 297.30% -5.20% 0.00%
EBITDA Growth
126.27% 57.71% -8.85% -34.70% -49.75% 0.00%
EBIT Growth
123.55% 58.69% -7.65% -35.65% -55.08% 0.00%
NOPAT Growth
127.13% 60.06% -8.34% -35.35% -55.08% 0.00%
Net Income Growth
109.65% 55.61% -6.67% -40.46% -55.76% 0.00%
EPS Growth
108.20% 57.19% 10.94% 77.40% -56.29% 0.00%
Operating Cash Flow Growth
459.42% -171.56% 309.28% -181.60% 234.69% 0.00%
Free Cash Flow Firm Growth
365.18% -176.50% 361.25% -124.54% 0.00% 0.00%
Invested Capital Growth
-44.93% 8.21% -72.13% -22.59% 0.00% 0.00%
Revenue Q/Q Growth
11.69% 8.04% 14.40% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-4.74% 23.97% -5.19% 0.00% 0.00% 0.00%
EBIT Q/Q Growth
-5.36% 24.02% -4.22% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth
-7.26% 24.63% -4.65% 0.00% 0.00% 0.00%
Net Income Q/Q Growth
-11.66% 22.09% -4.96% 0.00% 0.00% 0.00%
EPS Q/Q Growth
225.00% 23.27% -8.37% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
5.38% 34.83% 44.38% -42.84% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
6.03% 28.23% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
-21.39% -29.29% -20.52% 0.00% 0.00% 0.00%
Profitability Metrics
- - - - - -
Gross Margin
100.00% 100.00% 17.23% 11.68% 33.16% 16.37%
EBITDA Margin
0.69% -4.10% -14.35% -28.43% -83.85% -53.08%
Operating Margin
0.62% -4.02% -14.88% -29.61% -86.92% -53.13%
EBIT Margin
0.62% -4.14% -14.82% -29.68% -86.92% -53.13%
Profit (Net Income) Margin
0.28% -4.62% -15.38% -31.08% -87.91% -53.50%
Tax Burden Percent
78.15% 101.23% 99.91% 100.15% 100.26% 100.69%
Interest Burden Percent
58.48% 110.14% 103.85% 104.56% 100.87% 100.00%
Effective Tax Rate
21.85% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
2.87% -31.86% -53.35% -62.06% -90.60% 0.00%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
1.35% -5.97% -14.97% -19.51% -17.70% 0.00%
Return on Assets (ROA)
0.62% -6.66% -15.53% -20.43% -17.91% 0.00%
Return on Common Equity (ROCE)
2.86% -31.78% -53.18% -3.08% 261.49% 0.00%
Return on Equity Simple (ROE_SIMPLE)
2.58% -33.66% -68.46% -41.19% 31.39% 0.00%
Net Operating Profit after Tax (NOPAT)
45 -165 -413 -381 -282 -182
NOPAT Margin
0.49% -2.81% -10.42% -20.73% -60.84% -37.19%
Net Nonoperating Expense Percent (NNEP)
-0.59% -3.80% -7.19% -9.59% -17.84% 0.00%
Return On Investment Capital (ROIC_SIMPLE)
3.40% -14.93% -34.69% - - -
Cost of Revenue to Revenue
0.00% 0.00% 82.77% 88.32% 66.84% 83.63%
SG&A Expenses to Revenue
19.13% 24.32% 31.72% 14.42% 36.01% 22.67%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
99.38% 104.02% 32.11% 41.29% 120.08% 69.51%
Earnings before Interest and Taxes (EBIT)
57 -243 -587 -546 -402 -259
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
63 -241 -569 -523 -388 -259
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
3.28 2.57 0.59 1.19 0.00 0.00
Price to Tangible Book Value (P/TBV)
3.28 2.57 0.59 1.19 0.00 0.00
Price to Revenue (P/Rev)
0.36 0.35 0.13 0.89 3.12 2.96
Price to Earnings (P/E)
130.67 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 3.86 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 8.02 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 2.65 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.29 0.37 0.33 0.00 0.32 0.00
Long-Term Debt to Equity
0.29 0.37 0.33 0.00 0.32 0.00
Financial Leverage
-3.49 -3.28 -2.39 -2.15 -3.13 0.00
Leverage Ratio
4.63 4.79 3.43 3.04 5.06 0.00
Compound Leverage Factor
2.71 5.27 3.57 3.18 5.10 0.00
Debt to Total Capital
22.76% 27.04% 25.03% 0.00% 24.09% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
22.76% 27.04% 25.03% 0.00% 24.09% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.22% 0.19% 0.17% 0.38% 295.00% 0.00%
Common Equity to Total Capital
77.02% 72.76% 74.80% 99.62% -219.08% 0.00%
Debt to EBITDA
4.74 -1.24 -0.52 0.00 -0.37 0.00
Net Debt to EBITDA
-58.51 11.04 5.11 0.00 3.62 0.00
Long-Term Debt to EBITDA
4.74 -1.24 -0.52 0.00 -0.37 0.00
Debt to NOPAT
6.69 -1.81 -0.72 0.00 -0.51 0.00
Net Debt to NOPAT
-82.64 16.11 7.04 0.00 4.99 0.00
Long-Term Debt to NOPAT
6.69 -1.81 -0.72 0.00 -0.51 0.00
Altman Z-Score
1.48 0.94 -0.04 -0.16 -0.68 0.00
Noncontrolling Interest Sharing Ratio
0.27% 0.25% 0.32% 95.04% 388.61% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
0.82 1.26 1.26 1.24 1.12 0.00
Quick Ratio
0.71 1.14 0.97 0.99 0.76 0.00
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
876 -330 432 -165 674 0.00
Operating Cash Flow to CapEx
3,506.45% -1,064.08% 1,311.01% -702.12% 1,588.56% -636.14%
Free Cash Flow to Firm to Interest Expense
36.91 -13.43 19.09 -6.64 191.72 0.00
Operating Cash Flow to Interest Expense
41.21 -11.06 16.81 -7.30 63.38 0.00
Operating Cash Flow Less CapEx to Interest Expense
40.04 -12.10 15.53 -8.34 59.39 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
2.17 1.44 1.01 0.66 0.20 0.00
Accounts Receivable Turnover
35.49 28.07 22.34 18.05 7.08 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
142.59 96.26 74.44 44.62 12.92 0.00
Accounts Payable Turnover
0.00 0.00 12.32 8.72 2.25 0.00
Days Sales Outstanding (DSO)
10.28 13.00 16.34 20.22 51.52 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 29.63 41.84 162.26 0.00
Cash Conversion Cycle (CCC)
10.28 13.00 -13.29 -21.62 -110.74 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-2,682 -1,850 -2,016 -1,171 -955 0.00
Invested Capital Turnover
-4.05 -3.03 -2.49 -1.73 -0.97 0.00
Increase / (Decrease) in Invested Capital
-831 165 -845 -216 -955 0.00
Enterprise Value (EV)
-372 -585 -2,378 -914 1,785 0.00
Market Capitalization
3,323 2,069 528 1,645 1,445 1,445
Book Value per Share
$4.10 $3.56 $4.15 $6.62 ($44.28) $0.00
Tangible Book Value per Share
$4.10 $3.56 $4.15 $6.62 ($44.28) $0.00
Total Capital
1,316 1,105 1,190 1,393 592 0.00
Total Debt
300 299 298 0.00 142 0.00
Total Long-Term Debt
300 299 298 0.00 142 0.00
Net Debt
-3,698 -2,657 -2,908 -2,564 -1,404 0.00
Capital Expenditures (CapEx)
28 26 29 26 14 26
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2,770 -1,928 -2,098 -1,237 -990 0.00
Debt-free Net Working Capital (DFNWC)
-618 632 858 454 205 0.00
Net Working Capital (NWC)
-618 632 858 454 205 0.00
Net Nonoperating Expense (NNE)
19 106 197 190 125 80
Net Nonoperating Obligations (NNO)
-3,698 -2,657 -2,908 -2,564 -1,404 0.00
Total Depreciation and Amortization (D&A)
6.05 2.10 18 23 14 0.25
Debt-free, Cash-free Net Working Capital to Revenue
-30.18% -32.89% -52.94% -67.30% -213.86% 0.00%
Debt-free Net Working Capital to Revenue
-6.73% 10.78% 21.64% 24.67% 44.26% 0.00%
Net Working Capital to Revenue
-6.73% 10.78% 21.64% 24.67% 44.26% 0.00%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.11 ($1.22) ($2.85) ($3.20) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
240.39M 221.66M 212.47M 178.97M 0.00 0.00
Adjusted Diluted Earnings per Share
$0.10 ($1.22) ($2.85) ($3.20) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
265.85M 221.66M 212.47M 178.97M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
250.57M 229.73M 216.30M 210.40M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
45 -165 -413 -381 -282 -182
Normalized NOPAT Margin
0.49% -2.81% -10.42% -20.73% -60.84% -37.19%
Pre Tax Income Margin
0.36% -4.56% -15.39% -31.03% -87.68% -53.13%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
2.41 -9.86 -25.97 -21.92 -114.48 0.00
NOPAT to Interest Expense
1.89 -6.70 -18.25 -15.31 -80.13 0.00
EBIT Less CapEx to Interest Expense
1.23 -10.90 -27.25 -22.96 -118.47 0.00
NOPAT Less CapEx to Interest Expense
0.71 -7.74 -19.53 -16.35 -84.12 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -1.65% 0.00% -1.15%

Quarterly Metrics And Ratios for Oscar Health

This table displays calculated financial ratios and metrics derived from Oscar Health's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
42.20% 67.11% 68.30% 45.86% 45.77% 43.87% 47.17% 49.56% 51.08% 100.60% 120.38%
EBITDA Growth
57.64% -2.20% 19.90% 1,071.36% 653.06% 34.66% 69.07% 92.96% 48.79% -15.35% 10.60%
EBIT Growth
59.56% -2.24% 20.73% 922.26% 685.87% 34.69% 68.97% 92.30% 56.04% -12.68% 10.70%
NOPAT Growth
53.92% -1.55% 16.95% 1,470.87% 1,139.24% 34.61% 69.72% 93.87% 62.99% -13.36% 9.12%
Net Income Growth
55.23% -2.30% 17.22% 465.07% 547.87% 33.86% 66.05% 86.24% 48.75% -14.57% 8.48%
EPS Growth
48.39% 26.47% 24.14% 385.71% 444.44% 35.24% 68.13% 86.79% 50.00% -26.51% 10.78%
Operating Cash Flow Growth
38.49% 16.83% 56.48% 200.35% 52.96% 96.09% -109.58% -22.82% -26.32% 339.09% 6.94%
Free Cash Flow Firm Growth
1,754.00% 372.35% 363.62% -56.33% -88.69% -138.79% -150.54% -76.31% 74.80% 0.00% 550.72%
Invested Capital Growth
-42.79% -44.93% -54.36% -5.64% 4.86% 8.21% 14.44% -23.06% -34.80% -72.13% -70.76%
Revenue Q/Q Growth
27.33% -1.28% 9.20% 3.60% 49.64% -0.58% -5.36% 3.53% 47.69% 1.71% -3.82%
EBITDA Q/Q Growth
300.78% -220.94% -166.25% -63.07% 230.17% -151.54% -703.36% 78.98% 84.62% -19.09% -82.71%
EBIT Q/Q Growth
299.24% -217.58% -169.46% -63.69% 227.66% -146.22% -620.53% 74.13% 85.77% -16.98% -78.85%
NOPAT Q/Q Growth
374.65% -205.39% -154.05% -66.05% 281.20% -149.77% -792.08% 74.26% 88.60% -15.65% -80.65%
Net Income Q/Q Growth
279.73% -181.84% -196.58% -68.27% 218.45% -128.05% -325.95% 61.08% 82.51% -17.06% -72.62%
EPS Q/Q Growth
284.00% -127.27% -210.00% -67.74% 191.18% -134.48% -314.29% 61.11% 82.86% -15.38% -71.70%
Operating Cash Flow Q/Q Growth
153.31% 169.34% -200.60% -21.63% 113.69% 125.83% -794.32% -60.09% 173.93% 127.61% -355.69%
Free Cash Flow Firm Q/Q Growth
73.06% -2.18% 260.90% 203.45% 125.42% 5.31% -159.79% -21.43% -12.78% 23.38% -71.98%
Invested Capital Q/Q Growth
-21.41% -21.39% 17.81% -17.88% -23.22% -29.29% 43.75% -6.16% -18.89% -20.52% 19.10%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
25.82% 236.41% 100.00% 23.01% 27.43% 263.81% 19.22% 22.32% 100.00% 57.95% 12.85%
EBITDA Margin
9.63% -6.11% -1.88% 3.10% 8.69% -9.99% -3.95% -0.47% -2.29% -21.99% -18.78%
Operating Margin
9.75% -6.17% -2.00% 3.06% 8.66% -10.16% -4.04% -0.43% -1.73% -22.36% -19.66%
EBIT Margin
9.66% -6.17% -1.92% 3.02% 8.61% -10.09% -4.07% -0.54% -2.14% -22.22% -19.32%
Profit (Net Income) Margin
9.04% -6.41% -2.24% 2.54% 8.28% -10.47% -4.56% -1.01% -2.70% -22.77% -19.78%
Tax Burden Percent
95.59% 99.74% 103.97% 92.39% 99.44% 99.47% 101.41% 108.16% 105.37% 99.69% 99.17%
Interest Burden Percent
97.96% 104.08% 112.51% 91.05% 96.80% 104.30% 110.45% 175.18% 119.50% 102.77% 103.24%
Effective Tax Rate
4.41% 0.00% 0.00% 7.61% 0.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
10.47% 2.87% 2.83% 1.74% -5.44% -31.86% -34.63% -43.19% -50.45% -53.35% -44.03%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
18.97% -13.42% -4.03% 4.56% 12.64% -14.55% -5.77% -0.57% -2.16% -22.45% -17.90%
Return on Assets (ROA)
17.77% -13.93% -4.71% 3.84% 12.16% -15.10% -6.47% -1.08% -2.72% -23.00% -18.33%
Return on Common Equity (ROCE)
10.45% 2.86% 2.83% 1.74% -5.43% -31.78% -34.55% -43.08% -50.33% -53.18% -43.99%
Return on Equity Simple (ROE_SIMPLE)
9.31% 0.00% 2.54% 1.60% -5.18% 0.00% -37.77% -50.03% -61.52% 0.00% -53.67%
Net Operating Profit after Tax (NOPAT)
284 -103 -34 63 185 -102 -41 -4.57 -18 -156 -135
NOPAT Margin
9.32% -4.32% -1.40% 2.82% 8.61% -7.11% -2.83% -0.30% -1.21% -15.65% -13.76%
Net Nonoperating Expense Percent (NNEP)
-0.22% -1.57% -0.72% -0.17% -0.21% -1.73% -0.98% -0.32% -0.68% -2.59% -2.23%
Return On Investment Capital (ROIC_SIMPLE)
17.36% -7.86% - - - -9.22% - - - -13.08% -
Cost of Revenue to Revenue
74.18% -136.41% 0.00% 76.99% 72.57% -163.81% 80.78% 77.68% 0.00% 42.05% 87.15%
SG&A Expenses to Revenue
15.85% 19.47% 19.00% 19.61% 18.40% 25.44% 22.63% 22.16% 27.12% 102.85% 8.03%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
16.07% 242.58% 102.00% 19.95% 18.76% 273.97% 23.27% 22.74% 101.73% 80.31% 32.51%
Earnings before Interest and Taxes (EBIT)
294 -148 -46 67 184 -144 -59 -8.14 -31 -221 -189
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
293 -146 -46 69 186 -143 -57 -7.08 -34 -219 -184
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.46 3.28 4.41 3.30 3.26 2.57 1.34 1.85 1.52 0.59 0.98
Price to Tangible Book Value (P/TBV)
2.46 3.28 4.41 3.30 3.26 2.57 1.34 1.85 1.52 0.59 0.98
Price to Revenue (P/Rev)
0.33 0.36 0.62 0.52 0.51 0.35 0.23 0.35 0.32 0.13 0.31
Price to Earnings (P/E)
26.63 130.67 177.24 206.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
3.75% 0.77% 0.56% 0.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.21 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 26.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 29.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 36.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 1.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 2.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.22 0.29 0.26 0.26 0.29 0.37 0.32 0.31 0.32 0.33 0.27
Long-Term Debt to Equity
0.22 0.29 0.26 0.26 0.29 0.37 0.32 0.31 0.32 0.33 0.27
Financial Leverage
-3.34 -3.49 -2.74 -3.50 -3.38 -3.28 -2.55 -3.10 -2.84 -2.39 -2.01
Leverage Ratio
4.33 4.63 3.75 4.57 4.53 4.79 3.82 4.23 3.90 3.43 2.84
Compound Leverage Factor
4.24 4.82 4.22 4.16 4.38 4.99 4.22 7.42 4.66 3.53 2.93
Debt to Total Capital
18.32% 22.76% 20.44% 20.78% 22.42% 27.04% 24.47% 23.86% 24.24% 25.03% 21.54%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
18.32% 22.76% 20.44% 20.78% 22.42% 27.04% 24.47% 23.86% 24.24% 25.03% 21.54%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.19% 0.22% 0.18% 0.16% 0.17% 0.19% 0.16% 0.18% 0.18% 0.17% 0.18%
Common Equity to Total Capital
81.49% 77.02% 79.39% 79.06% 77.41% 72.76% 75.37% 75.95% 75.58% 74.80% 78.27%
Debt to EBITDA
1.76 4.74 4.51 5.44 -14.39 -1.24 -0.94 -0.67 -0.56 -0.52 -0.55
Net Debt to EBITDA
-26.93 -58.51 -50.86 -69.56 159.50 11.04 7.43 7.89 6.20 5.11 5.10
Long-Term Debt to EBITDA
1.76 4.74 4.51 5.44 -14.39 -1.24 -0.94 -0.67 -0.56 -0.52 -0.55
Debt to NOPAT
2.05 6.69 6.20 7.92 -17.30 -1.81 -1.36 -0.95 -0.78 -0.72 -0.75
Net Debt to NOPAT
-31.36 -82.64 -69.93 -101.37 191.76 16.11 10.75 11.18 8.70 7.04 6.99
Long-Term Debt to NOPAT
2.05 6.69 6.20 7.92 -17.30 -1.81 -1.36 -0.95 -0.78 -0.72 -0.75
Altman Z-Score
1.63 1.34 1.73 1.30 1.49 1.03 1.06 0.81 0.64 0.22 0.38
Noncontrolling Interest Sharing Ratio
0.23% 0.27% 0.22% 0.22% 0.23% 0.25% 0.22% 0.25% 0.23% 0.32% 0.10%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.91 0.82 0.80 0.96 1.16 1.26 1.45 1.29 1.30 1.26 1.38
Quick Ratio
0.84 0.71 0.68 0.87 1.06 1.14 1.29 1.16 1.14 0.97 1.07
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
1,260 728 744 206 68 -267 -282 472 601 689 558
Operating Cash Flow to CapEx
9,733.46% 5,086.08% -6,610.38% 6,574.33% 10,661.56% 4,865.09% -17,738.32% 2,946.84% 5,620.21% 2,123.34% -5,702.00%
Free Cash Flow to Firm to Interest Expense
210.17 120.80 127.97 34.42 11.51 -42.99 -46.05 77.15 97.94 112.31 91.17
Operating Cash Flow to Interest Expense
146.57 57.55 -86.01 82.98 107.48 47.75 -187.48 27.05 67.59 24.68 -89.51
Operating Cash Flow Less CapEx to Interest Expense
145.06 56.42 -87.31 81.72 106.47 46.77 -188.54 26.13 66.38 23.51 -91.08
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.96 2.17 2.10 1.51 1.47 1.44 1.42 1.07 1.01 1.01 0.93
Accounts Receivable Turnover
24.24 35.49 32.37 24.46 24.71 28.07 25.68 27.03 25.98 22.34 20.81
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
151.14 142.59 127.74 113.90 104.16 96.26 91.57 87.11 79.17 74.44 69.38
Accounts Payable Turnover
1.50 0.00 16.96 22.08 20.56 0.00 10.79 10.06 8.90 12.32 15.76
Days Sales Outstanding (DSO)
15.06 10.28 11.28 14.92 14.77 13.00 14.21 13.50 14.05 16.34 17.54
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
242.66 0.00 21.52 16.53 17.75 0.00 33.84 36.29 41.01 29.63 23.15
Cash Conversion Cycle (CCC)
-227.61 10.28 -10.24 -1.61 -2.98 13.00 -19.63 -22.79 -26.96 -13.29 -5.61
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-3,256 -2,682 -2,209 -2,688 -2,280 -1,850 -1,431 -2,544 -2,397 -2,016 -1,673
Invested Capital Turnover
-3.64 -4.05 -4.51 -2.76 -2.79 -3.03 -3.50 -2.15 -2.14 -2.49 -2.61
Increase / (Decrease) in Invested Capital
-976 -831 -778 -144 117 165 242 -477 -619 -845 -693
Enterprise Value (EV)
-1,304 -372 1,759 -73 50 -585 -1,115 -1,734 -1,912 -2,378 -1,696
Market Capitalization
3,285 3,323 5,131 3,753 3,362 2,069 1,236 1,760 1,415 528 1,059
Book Value per Share
$5.32 $4.10 $4.81 $4.80 $4.46 $3.56 $4.14 $4.35 $4.30 $4.15 $5.10
Tangible Book Value per Share
$5.32 $4.10 $4.81 $4.80 $4.46 $3.56 $4.14 $4.35 $4.30 $4.15 $5.10
Total Capital
1,636 1,316 1,465 1,440 1,333 1,105 1,220 1,250 1,230 1,190 1,382
Total Debt
300 300 299 299 299 299 299 298 298 298 298
Total Long-Term Debt
300 300 299 299 299 299 299 298 298 298 298
Net Debt
-4,592 -3,698 -3,375 -3,828 -3,314 -2,657 -2,353 -3,496 -3,328 -2,908 -2,757
Capital Expenditures (CapEx)
9.03 6.82 7.57 7.56 5.95 6.10 6.48 5.62 7.38 7.13 9.62
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3,362 -2,770 -2,297 -2,774 -2,363 -1,928 -1,513 -2,629 -2,485 -2,098 -1,753
Debt-free Net Working Capital (DFNWC)
-374 -618 -587 -143 484 632 931 948 950 858 1,079
Net Working Capital (NWC)
-374 -618 -587 -143 484 632 931 948 950 858 1,079
Net Nonoperating Expense (NNE)
8.52 50 21 6.34 7.04 48 25 11 22 71 59
Net Nonoperating Obligations (NNO)
-4,592 -3,698 -3,375 -3,828 -3,314 -2,657 -2,353 -3,496 -3,328 -2,908 -2,757
Total Depreciation and Amortization (D&A)
-0.75 1.51 0.96 1.80 1.78 1.42 1.80 1.06 -2.19 2.27 5.25
Debt-free, Cash-free Net Working Capital to Revenue
-33.35% -30.18% -27.95% -38.36% -36.15% -32.89% -27.89% -52.96% -55.70% -52.94% -50.58%
Debt-free Net Working Capital to Revenue
-3.71% -6.73% -7.14% -1.97% 7.41% 10.78% 17.15% 19.10% 21.29% 21.64% 31.13%
Net Working Capital to Revenue
-3.71% -6.73% -7.14% -1.97% 7.41% 10.78% 17.15% 19.10% 21.29% 21.64% 31.13%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.10 ($0.68) ($0.22) $0.24 $0.77 ($0.68) ($0.29) ($0.07) ($0.18) ($1.05) ($0.91)
Adjusted Weighted Average Basic Shares Outstanding
251.28M 240.39M 243.11M 238.67M 231.44M 221.66M 223.10M 219.40M 216.91M 212.48M 212.82M
Adjusted Diluted Earnings per Share
$0.92 ($0.50) ($0.22) $0.20 $0.62 ($0.68) ($0.29) ($0.07) ($0.18) ($1.05) ($0.91)
Adjusted Weighted Average Diluted Shares Outstanding
305.94M 265.85M 243.11M 303.97M 293.80M 221.66M 223.10M 219.40M 216.91M 212.48M 212.82M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
254.68M 250.57M 247.27M 241.91M 237.22M 229.73M 226.11M 221.91M 218.35M 216.30M 214.76M
Normalized Net Operating Profit after Tax (NOPAT)
284 -103 -34 63 185 -102 -41 -4.57 -18 -156 -135
Normalized NOPAT Margin
9.32% -4.32% -1.40% 2.82% 8.61% -7.11% -2.83% -0.30% -1.21% -15.65% -13.76%
Pre Tax Income Margin
9.46% -6.42% -2.16% 2.75% 8.33% -10.52% -4.50% -0.94% -2.56% -22.84% -19.95%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
49.08 -24.50 -8.00 11.17 31.24 -23.23 -9.57 -1.33 -5.13 -36.05 -30.86
NOPAT to Interest Expense
47.38 -17.16 -5.82 10.46 31.26 -16.38 -6.65 -0.75 -2.89 -25.38 -21.98
EBIT Less CapEx to Interest Expense
47.58 -25.64 -9.30 9.91 30.23 -24.21 -10.63 -2.25 -6.33 -37.21 -32.43
NOPAT Less CapEx to Interest Expense
45.88 -18.29 -7.12 9.20 30.26 -17.36 -7.71 -1.66 -4.10 -26.55 -23.55
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Oscar Health's Financials

When does Oscar Health's financial year end?

According to the most recent income statement we have on file, Oscar Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Oscar Health's net income changed over the last 5 years?

Oscar Health's net income appears to be on a downward trend, with a most recent value of $26.12 million in 2024, falling from -$261.18 million in 2019. The previous period was -$270.59 million in 2023. See where experts think Oscar Health is headed by visiting Oscar Health's forecast page.

What is Oscar Health's operating income?
Oscar Health's total operating income in 2024 was $57.27 million, based on the following breakdown:
  • Total Gross Profit: $9.18 billion
  • Total Operating Expenses: $9.12 billion
How has Oscar Health revenue changed over the last 5 years?

Over the last 5 years, Oscar Health's total revenue changed from $488.19 million in 2019 to $9.18 billion in 2024, a change of 1,779.9%.

How much debt does Oscar Health have?

Oscar Health's total liabilities were at $3.82 billion at the end of 2024, a 36.8% increase from 2023, and a 109.8% increase since 2020.

How much cash does Oscar Health have?

In the past 4 years, Oscar Health's cash and equivalents has ranged from $826.33 million in 2020 to $1.87 billion in 2023, and is currently $1.53 billion as of their latest financial filing in 2024.

How has Oscar Health's book value per share changed over the last 5 years?

Over the last 5 years, Oscar Health's book value per share changed from 0.00 in 2019 to 4.10 in 2024, a change of 409.9%.



This page (NYSE:OSCR) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners